280110-69-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-4-(5-Methyl-1,3,4-oxadiazol-2-yl)piperidine is used as a building block for the synthesis of various medicinally active molecules. Its unique structure and reactivity contribute to the development of new drugs and biologically active compounds, enhancing the therapeutic potential of pharmaceutical formulations.
Used in Agrochemical Industry:
1-Boc-4-(5-Methyl-1,3,4-oxadiazol-2-yl)piperidine is also used as an intermediate in the synthesis of agrochemicals, where its potential biological activity can be harnessed to create effective compounds for agricultural applications, such as pesticides or herbicides, to improve crop protection and yield.

InChI:InChI=1/C13H21N3O3/c1-9-14-15-11(18-9)10-5-7-16(8-6-10)12(17)19-13(2,3)4/h10H,5-8H2,1-4H3

Upstream product

• 18871-66-4 N,N-dimethylacetamide dimethyl acetal 
• 187834-88-4 tert-butyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 685827-77-4 tert-butyl 4-(2-acetylhydrazinecarbonyl)piperidine-1-carboxylate. 
• 78-39-7 Triethyl orthoacetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 859154-07-7 4-[4-(4-chloro-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidine 
• 280110-76-1 2-methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride 
• 2442597-61-5 4-(5-methyl-[1,3,4]oxadiazol-2-yl)-piperidine hydrobromide 
• 859154-08-8 4-[4-(4-chloro-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidine hydrochloride 
• 859155-62-7 4-[4-(4-chloro-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidine 
• 685827-98-9 4-(4-benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Development of autotaxin inhibitors: A series of tetrazole cinnamides

A series of inhibitors of Autotaxin (ATX) have been developed from a high throughput screening hit, 1a, which shows an alternative binding mode to known catalytic site inhibitors. Selectivity over the hERG channel and microsomal clearance were dependent on the lipophilicity of the compounds, and this was optimised by reduction of clogD whilst maintaining high affinity ATX inhibition. Compound 15a shows good oral exposure, and concentration dependent inhibition of formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic (PK/PD) experiments.

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, e

AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.

TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents a group selected from H, CF3, and C1-6 alkyl (optionally substituted by C1-6 alkyloxy or triazolyl); R2/

Compounds useful in therapy

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: X represents —[CH2]a—R or —[CH2]a—O—[CH2]b—R; a represents a number selected from 0 to 6; b represents a number selected from 0 to 6; R represents H, CF3 or Het; Het represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; Y represents one or more substituents independently selected from —[O]c—[CH2]d—R1, which may be the same or different at each occurrence; c at each occurrence independently represents a number selected from 0 or 1; d at each occurrence independently represents a number selected from 0 to 6; R1 at each occurrence independently represents H, halo, CF3, CN or Het1; Het1 at each occurrence independently represents a 5- or 6-membered unsaturated heterocyclic ring; V represents a direct link or —O—; Ring A represents an optionally substituted 5- to 7-membered saturated heterocyclic ring, or a phenylene group; Q represents a direct link or —N(R2)—; R2 represents hydrogen or C1-6 alkyl; Z represents —[O]e—[CH2]f—R3, a phenyl ring (optionally fused to a benzene ring or Het2, and the group as a whole being optionally substituted), or Het3 (optionally fused to an benzene ring or Het4, and the group as a whole being optionally substituted); R3 represents C1-6 alkyl (optionally substituted), C3-6 cycloalkyl, C3-6 cycloalkenyl, phenyl (optionally substituted), Het5 or NR4R5; e represents a number selected from 0 or 1; f represents a number selected from 0 to 6; Het2 and Het5 independently represent optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic rings; Het3 represents an optionally substituted 4 to 6-membered saturated, partially saturated or aromatic heterocyclic ring; Het4 represents an optionally substituted 6-membered aromatic heterocyclic ring; R4 and R5 independently represent optionally substituted C1-6 alkyl, C1-6 alkyloxy, C3-8 cycloalkyl (optionally fused to C3-8 cycloalkyl), Het6, or hydrogen; Het6 represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; are useful for treating a disorder for which a V1a antagonist is indicated.